Recent literature suggests that after non-myeloablative allogeneic (NMA) stem cell transplantation (SCT), the incidence of extramedullary (EM) relapse in multiple myeloma (MM) patients is increased and that these relapses have a poor prognosis. However, numbers on incidence and treatment outcome are scarce. We collected data from 54 relapsed MM patients from a total group of 172 treated with sequential autologous and allogeneic NMA SCT at seven transplantation centres. There were 43 (79.6%) systemic relapses, including 6 with concurrent EM localisation. Five patients had a local EM relapse only. Six patients relapsed with only bone involvement. Patients with deletion of chromosome 13 had a higher incidence of EM relapse (30.8 versus 5.6%, P ¼ 0.06). EM relapses were treated with donor lymphocyte infusion, radiotherapy, or chemotherapy, especially with novel agents. The response rate was 45.5%, which was not different when compared to patients without EM disease (54.1%). Overall survival and progression-free survival were not significantly different in patients with EM disease, when compared to those without EM disease. In conclusion, the incidence of relapse with EM disease following allogeneic NMA SCT was 20.4%. There was no negative impact of EM relapse on response rate, overall survival and progression-free survival.
Introduction
The tandem of autologous stem cell transplantation (SCT) followed by non-myeloablative allogeneic (NMA) SCT in the treatment of multiple myeloma (MM) seems to be an effective regimen with a low treatment-related mortality as compared to allogeneic myeloablative (MA) SCT. 1 Due to the graft-versus-myeloma (GVM) effect long-lasting remissions have been demonstrated. 2 However, there is an impression that the incidence of extramedullary (EM) relapses is increased after this procedure as compared to allogeneic MA SCT. In a recent study, 10 out of 27 (37%) relapses after allogeneic NMA SCT occurred at EM sites, with predominance of cranial and periorbital localisation. However, no information was given on the treatment and outcome of these EM relapses. 3 Previous reports on the incidence of EM relapse are of MM patients who received an allogeneic MA SCT. Byrne et al. 4 published a series of 18 MA-transplanted patients with a follow-up of 5.3 years of whom 7 relapsed. One patient (14%) with a systemic relapse also had an EM localisation (skin). This low EM relapse rate is in accordance with Terpos et al. 5 who reported one EM relapse in 16 allogeneic MA-transplanted patients. Zeiser et al. 6 published a series of 37 MM patients with a MA allogeneic SCT of whom 25 relapsed during a follow-up of 28 months. This was a poor prognostic group with several unfavourable risk factors such as advanced age, more prior lines of therapy and more advanced disease as compared to the patients undergoing an autologous SCT being described in the same publication. In the whole group of relapsed patients, EM relapse, defined as at least one EM manifestation of MM, was detected in 32% of the allogeneic MA SCT patients. These patients with EM relapse had higher b2-microglobulin levels at presentation and more frequent 13q deletions. There was no difference in overall survival (OS) between the EM and bone marrow relapses for the allogeneic MA SCT patients and also response to treatment was similar (50 and 54%, respectively).
Besides these series, there are few anecdotal publications on the occurrence of EM relapses after both MA and reduced intensity allogeneic SCT and the treatment of these relapses.
7,8 Therefore, we investigated the incidence and treatment of EM relapses in a large group of MM patients, all treated with an autologous SCT followed within 2-6 months by allogeneic NMA SCT.
Patients and methods
A questionnaire was sent to six academic transplant centres in the Netherlands and one in Germany in May 2006. All patients, who received their allogeneic NMA SCT with a related or unrelated donor within 2-6 months after the autologous SCT and relapsed afterwards were included. Both newly diagnosed as well as relapsed MM patients before the autologous SCT were eligible. For sufficient follow-up time, the allogeneic SCT had to be performed before the first of January 2006.
Information was gathered on the type of relapse (systemic relapse with or without EM disease, or local EM relapse), the association with prognostic factors, type of treatment before the relapse, response, GVHD and the treatment of these relapses.
Definitions
Systemic relapse was defined as more than 10% monoclonal plasma cells in the bone marrow (5% in case of relapse from CR), combined with increase of monoclonal protein in the serum or urine of more than 25% from baseline (except in case of dedifferentiation).
9 EM plasmacytoma was defined as a plasma cell tumour outside the bone marrow and not originating from skeletal structures. 10 Bone lesions were defined as new lytic lesions on X-ray or solitary plasmacytomas originating from bone. 10 For diagnosing and grading of acute GVHD, the Glucksberg criteria were used. 11 Chronic GVHD was graded according to the Seattle classification. 12 Response and progression were assessed according to the European Group for Blood and Marrow Transplantation criteria 13 and for EM relapses according to the response criteria of non-Hodgkin's lymphomas. 14 
Statistical analysis
For the statistical analysis SPSS 12.0.1 for Windows (SPSS Inc., IL, USA) was used. OS was measured in years and defined as the time from the date of relapse following allogeneic NMA SCT until the date of death or last followup. Progression-free survival (PFS) was measured in years and defined as the time from the date of relapse following allogeneic NMA SCT until the date of progression or death from any cause or last follow-up.
Probabilities of OS and PFS were calculated using the Kaplan-Meier method. Kaplan-Meier curves were generated to illustrate survival and the log-rank test was used to compare survival curves between subgroups. Univariate Cox's regression analysis was used to determine the prognostic value of various variables for OS and PFS. Comparisons between groups were made by the Mann-Whitney U-test for continuous data. For categorical data, comparisons between groups were made by using the Fisher's exact test for two by two tables and otherwise with the Pearson's w 2 -test. All quoted P-values are from two-sided tests, and values of less than 0.05 were considered significant.
Results

Patient characteristics
In total 172 patients from seven transplant centres were treated with sequential autologous-allogeneic NMA SCT. The conditioning for the autologous SCT consisted of melphalan 200 mg/m 2 in 2 days for all patients, except in patients with a creatinine clearance less than 40 ml/min who received 100 mg/m 2 in 1 day. Of these patients, 54 (31.4%) relapsed and were included in this study ( Table 1 ). The median interval between allogeneic NMA SCT and relapse Forty-two patients (77.8%) had a matched related donor, three patients (5.6%) had a partially matched related donor, and nine patients (16.7%) had a matched unrelated donor. Thirty-one patients (57.4%) were conditioned with total body irradiation (TBI) only (2 Gy), 18 (33.3%) with TBI and fludarabine (30 mg/m 2 per day for 3 days) and 5 (9.3%) with TBI, fludarabine and anti-thymocyte globulin (ATG).
In the post transplantation period, all patients were treated with the immunosuppressive drugs cyclosporine (CYA) and mycophenolate mofetil (MMF). Patients received 30 mg/kg per day MMF for 60-90 days and 2 Â 4.5 mg/kg per day CYA for 3-6 months.
At the time of diagnosis, 26 out of 44 patients (59.1%) had chromosome 13 abnormalities in FISH-analysis, 5 out of 47 (10.6%) patients had an elevated lactate dehydrogenase (LDH) and 23 out of 46 patients (50%) had an elevated b2-microglobulin (43.0 mg/l).
Type of relapse A total of 43 out of 54 relapses (79.6%) were systemic relapses, including 6 with also EM localisation of disease (11.1%). These EM relapses were located in the skin in three patients, glottis in one patient, pleural effusion in one patient and one patient had EM plasmacytomas in the kidney and intra-abdominal lymph nodes (Table 2) . A total of 5 out of 54 patients had EM relapse only (9.3%); 2 patients presented with soft tissue plasmacytomas, 1 with a skin plasmacytoma, 1 with lung and skin plasmacytomas and 1 with plasmacytomas in the kidney, skin and lymph nodes ( Table 2 ). The morphology of the EM relapses showed atypical plasma cells with plasmablastic appearance and mitotic figures in 7 out of 11 cases. This appearance was seen in only one bone marrow biopsy from the patient group with systemic relapse combined with EM relapse. Six patients relapsed with bone disease only, that is, new lytic lesions or a plasmacytoma originating from bone.
In total 11 patients (20.4%) presented with EM disease at relapse following allogeneic NMA SCT. The induction treatment before autologous SCT in these patients consisted of three courses of adriamycin, dexamethasone (one patient), either combined with vincristine (five patients) or thalidomide (five patients). All patients were mobilised with cyclophosphamide, mostly combined with adriamycin and dexamethasone (eight patients). The presence of deletion of chromosome 13 at diagnosis was associated with a higher incidence of EM relapse (P ¼ 0.06). The incidence of EM relapse was 30.8% in patients with deletion of chromosome 13, whereas it was only 5.6% in patients without this deletion. All other factors including elevated LDH, elevated b2-microglobulin and albumin level at diagnosis, age at allogeneic NMA SCT, gender, type of heavy chain, type of light chain, stage according to Durie-Salmon, acute GVHD, chronic GVHD, chimaerism of peripheral blood cells at 3 months after NMA allogeneic SCT, conditioning regimen, use of ATG, stem cell source (related versus unrelated donor), mismatch, relapse before autologous SCT, response at time of allogeneic SCT and response to allogeneic SCT were not associated with the presence of EM disease at relapse following allogeneic NMA SCT.
Response to relapse treatment Relapse was treated with donor lymphocyte infusions (DLIs) in 21 patients (38.9%), radiotherapy in 19 patients (35.2%) and reinduction chemotherapy in 41 patients (75.9%). Treatment consisted of a single treatment modality or a combination of different modalities. Thalidomide was most frequently used as reinduction therapy, either as single agent (15 patients) or in combination with dexamethasone (11 patients), or other drugs (2 patients). One patient was treated with thalidomide in combination with bortezomib and six patients were treated with bortezomib only. Other therapies were melphalan with prednisone (two patients) or with dexamethasone (one patient). Two patients were treated with vincristine, adriamycin and dexamethasone, one patient with dexamethasone only. In total, 1 patient achieved a MR, 10 patients a PR, 3 patients a VGPR, 11 patients a CR and 6 patients could not be evaluated because follow-up was less than 3 months following relapse treatment. This results in a total response rate of 52.1% of patients. EM relapse was treated with DLI in three patients (27.3%), radiotherapy in four patients (36.4%) and chemotherapy in nine patients (81.8%) ( Table 2) . Chemotherapy consisted mostly of thalidomide (six patients), dexamethasone (two patients) or bortezomib (two patients). There was no significant difference in response rate in patients with EM disease at relapse (45.5%), when compared to those without EM disease at relapse (54.1%; P ¼ 0.736). The response rate of patients with EM disease treated with the novel agents thalidomide or bortezomib in combination with other treatment modalities was 63% ( Table 2 ). Patients that initially responded to allogeneic NMA SCT showed a higher response rate to relapse treatment, when compared with those who did not respond to the allogeneic SCT (response rate, 62.9 versus 23.1%; P ¼ 0.022). All other factors tested were not predictive of response.
Overall survival
Median OS following relapse after allogeneic NMA SCT was 2.6 years (range, 0.1-3.7 þ years) (Figure 1a) .
There was no significant difference in OS in patients with EM disease at relapse, when compared to those without EM disease (1-year survival 61 versus 73%, respectively; P ¼ 0.494) (Figure 2a) . Furthermore, there was no difference in OS between patients with local EM disease and EM disease in combination with systemic relapse. OS was significantly longer in patients responding to relapse treatment, when compared to non-responding patients (Po0.001) (Figure 2b) . Patients with an elevated b2-microglobulin at diagnosis (43 mg/l) (Figure 2c ) or relapse prior to autologous SCT (Figure 2d) showed a shorter OS, when compared to those with b2-microglobulin p3 mg/l (P ¼ 0.012) or without relapse prior to autologous SCT (P ¼ 0.002). Achievement of a response to allogeneic NMA SCT was associated with a longer OS, when compared with patients who did not respond (P ¼ 0.010) (Figure 2e ). Patients with low LDH or with chronic GVHD had an improved OS with borderline significance, when compared with those with elevated LDH (P ¼ 0.077) or without chronic GVHD (P ¼ 0.079). All other variables tested were not predictive for OS.
Progression-free survival
Median PFS following relapse after allogeneic NMA SCT was 2.4 years (range, 0-3.4 þ years) (Figure 1b) . Univariate Cox's regression analysis showed that PFS was not significantly different between patients with or without EM disease at relapse (P ¼ 0.36) (Figure 3a) . Furthermore, there was no difference in PFS between patients with local EM disease and EM disease in combination with systemic relapse.
PFS was significantly longer in patients obtaining PR, VGPR or CR following relapse treatment, when compared to those with stable disease or minor response (P ¼ 0.027) (Figure 3b ). Patients with an elevated b2-microglobulin (43 mg/l) had a shorter PFS, when compared to those with b2-microglobulin p3 mg/l (P ¼ 0.02) (Figure 3c ).
Patients with relapse prior to autologous SCT or less than 95% donor chimaerism at 3 months following NMA allogeneic SCT had an inferior PFS with borderline significance, when compared with those without relapse prior to autologous SCT (P ¼ 0.058) or with 495% donor chimaerism at 3 months (P ¼ 0.071). All other variables tested were not predictive for PFS.
Discussion
There is a general concern that with the introduction of NMA transplantation, the incidence of EM relapses is increasing. This is not only reported for MM, but also for acute leukaemias. 15, 16 These EM relapses are believed to indicate transformation of the disease, associated with a more aggressive behaviour, therapy resistance and short survival. However, reports regarding this subject in MM are lacking data on the efficacy of the relapse treatment or are case reports.
We found an incidence of EM relapse of 20.4% in the largest series published so far. This is lower than the incidence of 37% reported by Perez-Simon et al.
3 which can be explained by the differences in patient populations studied. All our patients received the sequential autologous-allogeneic NMA SCT approach and none were progressive at the time of the allogeneic SCT. In the former study, only 21.4% of patients underwent the sequential approach and 30% were progressive at the time of transplant. In a prognostic worse cohort of 25 MAtransplanted patients, the EM relapse rate was 32%. 6 This suggests that the most important factor is not the induction therapy before allogeneic SCT but the status of the disease at the time of transplantation. Allogeneic transplantation in progressive patients may enhance the risk of EM relapse.
A much lower incidence of EM relapses of 9-13% has been reported after autologous SCT. 5, 6 Reasons for this discrepancy are not clear but may be due to the allogeneic transplant itself or the immunosuppressive regimen used after transplant. Another explanation might be that the GVM is more effective in the bone marrow than at EM sites, thereby predisposing allogeneic SCT patients to this type of relapse. However, the association of chronic GVHD with EM relapse demonstrated by others could not be confirmed in our study. 3, 15 Also, the hypothesis of relative resistance of EM disease to GVM effects is in contrast with the effect of DLI on EM relapse. In our patient group, two out of three patients with EM disease at relapse obtained CR to DLI. However, we cannot state with certainty that remission was caused by DLI, as concomitant treatment with bortezomib or thalidomide was given. Others have reported an effect by DLI treatment alone in three out of four patients with EM relapse, indicating that GVM can be effective in EM relapses. 6 The biological behaviour of (a subclone of) plasma cells already present before the allogeneic transplant might influence the type of relapse after transplant. In accordance with Zeiser et al., 6 we demonstrated that the presence of deletion of chromosome 13 at diagnosis, which is an established poor prognostic factor, is also a risk factor for the occurrence of EM relapse. Others have demonstrated a relation of this deletion with central nervous system relapse. 17 This suggests that the homing behaviour of plasma cells out of the bone marrow environment may be influenced by this cytogenetic abnormality.
The response to therapy was similar in patients with EM disease (45.5%), when compared to those without EM disease (54.1%). Moreover, the OS and PFS were also similar between these two groups, contesting the idea of a poor prognosis of EM disease after allogeneic SCT.
Eight patients with EM relapse received thalidomide or bortezomib in combination with another treatment modality and five of these responded (response rate 63%). Two patients treated with monotherapy consisting of dexamethasone or radiotherapy showed progressive disease. The use of these novel agents for the treatment of relapse after allogeneic SCT appears to be very successful. Biagi et al. 8 have shown a good response in three patients treated with thalidomide 300-800 mg daily without the use of DLI. This was also shown by Van de Donk et al. 18 for the treatment of non-EM relapses or progressive disease not responsive to DLI.
In conclusion, we have shown an incidence of EM relapse of 20.4% in a large cohort of MM patients treated with autologous SCT followed by allogeneic NMA SCT. Treatment with novel agents combined with DLI and/or RT resulted in a response rate of 63% in patients with EM disease and a similar OS and PFS compared to those without EM relapse.
